White Paper
The Pivotal Role of Packaging in Patient Safety
Why the integrity of primary packaging for injectable drugs is inseparable from patient safety — and how manufacturing excellence is the foundation of both.
Status
Published
Format
White Paper
Language
English
Access
Registration Required
Resource Overview
About this White Paper
For injectable drug products, primary packaging is not merely a container — it is an active safety system. Unlike oral drugs, injectables bypass the body's natural filtration mechanisms entirely, meaning any contamination introduced through the container closure system enters the bloodstream directly. This 2022 report by Datwyler examines the full spectrum of patient safety risks associated with parenteral packaging, including container closure integrity (CCI) failures, extractables and leachables (E&L) interactions with sensitive biologics, visible and sub-visible particulate contamination, and the self-sealing performance of multi-dose elastomeric closures.
The report highlights the growing importance of home care drug delivery — prefilled syringes and autoinjectors — where packaging must maintain integrity outside the controlled hospital environment. It then outlines how Datwyler's FirstLine® manufacturing standard directly addresses these risks through ISO 5 cleanroom environments, 100% automated camera inspection, metal detection, a zero-defect design philosophy, and fluoropolymer-coated components including OmniFlex® stoppers and NeoFlex™ plungers. The report also covers material selection considerations — elastomer geometry, sterilization compatibility, silicone oil avoidance — positioning Datwyler as a quality-by-design partner for pharmaceutical and biotech companies seeking to protect patients and reduce recall risk.
Access This Resource
Download the White Paper
Continue to access the full resource.
Access the White Paper
Quick access in under 30 seconds.
